A unique focus targeting non-motor symptoms in Parkinson’s Disease and targeting agitation in Alzheimer’s and dementia
There are 1 million Americans suffering with Parkinson’s Disease. It is a complex, chronic, progressive, neurodegenerative disease with no cure. It continues to have significant unmet needs in non-motor symptoms such as PD specific anxiety, depression, sleep disorders and pain.
Non-motor symptoms can often be more detrimental to patients’ overall well being and quality of life and can be related to Parkinson’s itself, or from the medications used to treat it. For non-motor symptom management, pharmacotherapy selection can be based on considerations of safety and tolerability, and none of the drugs have shown clear difference in controlling non-motor symptoms in Parkinson’s Disease specific populations. A new solution is needed.
There are over 7 million Americans suffering with Alzheimer’s and dementia. It is a complex, chronic, progressive, neurodegenerative disease with no cure. It is estimated that 40% to 70% of patients suffer from agitation, which is among the most persistent, complex, stressful, and costly aspects of care among patients with dementia, and is associated with disease progression.
Current therapies for agitation have modest efficacy and many have safety concerns that include an increased risk of seizures, stroke, or death.
Agitation significantly increases the cost burden on families, caregivers and the healthcare system, and is linked to an increased risk of distress, physical and mental exhaustion, burn out, clinical depression and health issues for families and caregivers. It is a significant unmet need.
Pike is developing a novel multi-day, continuous delivery dronabinol matrix patch to target relief for patients, families, and the healthcare system.